My ePortfolio Register   

ShortHER trastuzumab treatment of HER2 breast cancer: 9 weeks v 1 year

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 05.06.17
Views: 397
Rating:

Prof Pierfranco Conte - Istituto Oncologico Veneto, Padova, Italy

Prof Conte speaks with ecancer at ASCO 2017 about the outcomes of the ShortHER trial, a non-inferiority assessment of 9 weeks trastuzumab with chemotherapy for HER2 breast cancer compared to standard therapy of a year.

He outlines the patients recruited, including those with multiple positive nodes, and describes survival rates at 5 years.

Statistical analysis of patient survival and response shows that the shorer course fell marginally short of the boundaries for non-inferiority, when considering all patients including those with 4 positive nodes, though notes that the reduced course also featured sparing of cardiac toxicity, and confidence in its non-inferiority can be scored at 78%.

Taking these results into consideration, a shorter course of trastuzumab may be considered safe and efficacious for low-risk HER2 breast cancer patients (<3 positive nodes), when cardiac toxicity is of greater concern or for resource-limited regions.

Prof Conte lists similar trials ongoing internationally comparing 6 months of trastuzumab to 1 year, and considers how a short-course of a biosimilar may be an option for further trials.

These results are also discussed by Prof Valentina Gaurneri here.

Related videos

follow us



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence